To ask the Minister of Health whether he will be reviewing the guidance around eligibility for prostate cancer testing, in line with the review announced in England.

Screening for prostate cancer is currently not recommended by the UK National Screening Committee (UK NSC), an independent scientific committee which advises the four nations. They last considered the evidence for screening for prostate cancer in 2020 and concluded that screening was not recommended. This is because of the poor ability of the prostate specific antigen (PSA) test to predict cancer, which could lead to unnecessary tests that carry risks of potentially life-changing harm. Additionally, some prostate cancers may not produce elevated PSA levels, leading to false-negative results that provide false reassurance.

The UK NSC has commissioned a prostate cancer screening evidence review and cost effectiveness model, and it is expected to review this work during 2025. The UK NSC process will include a public consultation.

The UK Health Departments, through the National Institute of Health and Care Research (NIHR), have invested in a significant programme of research to address the evidence gaps in this important area. A clinical trial (called the TRANSFORM trial), which will compare the most promising tests and provide evidence about the best way to screen for prostate cancer, is due to start in early 2025.

My department will continue to be guided by the UK NSC’s recommendations on proposals for screening programmes.

Anyone with symptoms which they believe may be related to the prostate gland should contact their GP.